Eukaryote – Talk Bio

Fosun Licenses Immunology Asset FXS6837 to Sitala in $670M Deal

2 weeks ago talkbio0Tagged Autoimmune Diseases, Fosun Pharma, FXS6837, Immunology, License, Sitala

Fosun Pharma; Sitala; FXS6837; immunology; license agreement; autoimmune diseases; biotech; pharmaceuticals; $670 million

Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times

2 weeks ago talkbio0Tagged adaptation, Apis (invertebrate), Clinical Trials, drug price, Generalized, Investments, manufacturing uncertainty, Market, Pharma, Policy, regulatory environment, Reinvention, resilience, strategic reserves, supply chain

pharma; resilience; reinvention; supply chain; manufacturing uncertainty; regulatory environment; global market adaptation; funding; investment; clinical trials; drug pricing policy; APIs; strategic reserves

FDA may not renew Pfizer’s pediatric COVID-19 shot authorization, creating uncertainty for fall child vaccinations

4 weeks ago talkbio0Tagged Advice, authorization, Centers for Disease Control and Prevention (U.S.), Child, Comparison, COVID19 (disease), EUA, Eua (gastropod), Moderna, Pediatric brand name, Pfizer-BioNTech, Regulatory Framework, renewal, United States Food and Drug Administration, Vaccination, Vaccines

FDA; Pfizer-BioNTech; pediatric COVID-19 vaccine; EUA renewal; authorization not renewed; child vaccinations; fall 2025; regulatory framework; Moderna comparison; CDC guidance

Two Courts Reject Challenges to Inflation Reduction Act, Marking Major Win for Government

1 month ago talkbio0Tagged administrative law, AstraZeneca, constitutional challenge, Drug Negotiation Program, federal courts, Inflation, Ira (eukaryote), Medicare, Myasthenic Syndromes, Congenital, Third Circuit Court

Inflation Reduction Act; IRA; Medicare Drug Negotiation Program; AstraZeneca; federal courts; constitutional challenge; administrative law; Third Circuit Court; CMS; Medicare

Senate Drops Orphan Cures Act from Trump’s Tax Bill, Dealing Setback to Biopharma

3 months ago talkbio0Tagged Beak, Big Beautiful Bill, Biopharma, Drugs, Orphan, healthcare legislation, Infrequent, Ira (eukaryote), Mediation, Orphan Cures Act, Prices, reconciliation, Senate, Transplant Registry Unified Management Program

Orphan Cures Act; orphan drugs; Trump tax bill; biopharma; Senate; IRA price negotiations; rare diseases; Big Beautiful Bill; healthcare legislation; reconciliation bill

Antares Therapeutics Launches with $177M to Tackle ‘Undruggable’ Targets After Scorpion Spinout

3 months ago talkbio0Tagged Antares, biotech spinoff, Eli Lilly acquisition, Neoplasms, Precision Medicine, preclinical pipeline, Scorpions, targets

Antares Therapeutics; Scorpion Therapeutics; biotech spinoff; $177M Series A; undruggable targets; oncology; precision medicine; Eli Lilly acquisition; preclinical pipeline

Arcturus Prunes Early-Stage Pipeline to Focus on mRNA Therapies

4 months ago talkbio0Tagged Arcturus, biotech strategy, cash runway, Cystic Fibrosis, Kostaive, mRNA therapies, Ornithine carbamoyltransferase deficiency, pipeline reduction, vaccine programs

Arcturus Therapeutics; pipeline reduction; mRNA therapies; cystic fibrosis; ornithine transcarbamylase deficiency; Kostaive; vaccine programs; biotech strategy; cash runway